Landscape of KRAS^G12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers.

ABSTRACT:

Purpose

Promising single-agent activity from sotorasib and adagrasib in KRAS^G12C-mutant tumors has provided clinical evidence of effective KRAS signaling inhibition. However, comprehensive analysis of KRAS-variant prevalence, genomic alterations, and the relationship between KRAS and immuno-oncology biomarkers is lacking.

Materials and methods

Retrospective analysis of deidentified records from 79,004 patients with various cancers who underwent next-generation sequencing was performed. Fisher's exact test evaluated the association between cancer subtypes and KRAS variants. Logistic regression assessed KRAS^G12C comutations with other oncogenes and the association between KRAS variants and immuno-oncology biomarke

SUBMITTER: Salem ME 

PROVIDER: S-EPMC8966967 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature